MaaT Pharm, which stands for Microbiota as a Therapy, is a clinical-stage biotechnology company that has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases.
MaaT Pharma is committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation.
MaaT Pharma was founded in 2014 by Hervé Affagard and Joël Doré. The company is based in Lyon, Rhone-Alpes, France.
MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients and a Phase 2 clinical trial in acute GvHD is ongoing.
MaaT Pharma's pipeline include GutPrint, a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions.
MaaT Pharma’s GutPrint® will enable computational data science platform, the new industrial fermentation platform to develop and manufacture both “standard” high-richness, high-diversity fermented product MaaT034, and a pipeline of indication-specific candidates.
MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.
MaaT Pharma is backed by SymBiosis, PSIM Fund, Seventure Partners, SkyViews Life Science, Celeste Management and others. The company raised an additional €7.35M ($8.7M) in an extension of its Series B on Dec 01, 2020. This brings MaaT Pharma's total funding to €37.4M to date.